Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2020

01-01-2020 | Parathyroid Cancer | Original Article

Long-term remission of disseminated parathyroid cancer following immunotherapy

Authors: Marta Sarquis, Stephen J. Marx, Albert Beckers, Arthur R. Bradwell, William F. Simonds, Maria Aparecida C. Bicalho, Adrian F. Daly, Daniela Betea, Eitan Friedman, Luiz De Marco

Published in: Endocrine | Issue 1/2020

Login to get access

Abstract

Purpose

Parathyroid cancer is a rare tumor associated with poor prognosis particularly when disseminated. While chemotherapy and/or radiotherapy are of no clinical value in disseminated disease, immunotherapy should be considered.

Subject and results

A patient with CDC73-associated metastatic parathyroid carcinoma was treated with combined anti-hPTH immunotherapy and surgery.

Conclusions

Following five courses of anti-hPTH immunotherapy and subsequent surgery, a 12-year long remission of disseminated parathyroid cancer is reported. This case further supports the ever-expanding spectrum of cancers that may benefit from immunotherapy.
Literature
1.
C. Sadler, C. Sadler, K.W. Gow, E.A. Beierle, J.J. Doski, M. Langer, J.G. Nuchtern, S.A. Vasudevan, M. Goldfarb, Parathyroid carcinoma in more than 1,000 patients: a population-level analysis. Surgery 156, 1622–1629 (2014)CrossRef
2.
D. Betea, I. Potorac, A. Beckers, Parathyroid carcinoma: challenges in diagnosis and treatment. Ann. Endocrinol. 76, 169–177 (2015)CrossRef
3.
A.S. Salcuni, F. Cetani, V. Guarnieri, V. Nicastro, E. Romagnoli, D. de Martino, A. Scillitani, D.E.C. Cole, Parathyroid carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 32, 877–889 (2018)CrossRef
4.
K. Brewer., J. Costa-Guda, A. Arnold, Molecular genetic insights into sporadic primary hyperparathyroidism. Endocr. Relat. Cancer 26, R53–R72 (2019)CrossRef
5.
E. Cavalier, A.F. Daly, D. Betea, P.N. Pruteanu-Apetrii, P. Delanaye, P. Stubbs, A.R. Bradwell, J.P. Chapelle, A. Beckers, The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker of parathyroid carcinoma. J. Clin. Endocrinol. Metab. 95, 3745–3749 (2010)CrossRef
6.
A. Harari, A. Waring, G. Fernandez-Ranvier, J. Hwang, I. Suh, E. Mitmaker, W. Shen, J. Gosnell, Q.Y. Duh, O. Clark, Parathyroid carcinoma: a 43-year outcome and survival analysis. J. Clin. Endocrinol. Metab. 96, 3679–3686 (2011)CrossRef
7.
E.A. Asare, C. Sturgeon, D.J. Winchester, L. Liu, B. Palis, N.D. Perrier, D.B. Evans, D.P. Winchester, T.S. Wang, Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann. Surg. Oncol. 22, 3990–3995 (2015)CrossRef
8.
Y. Takeuchi, S. Takahashi, D. Miura, M. Katagiri, N. Nakashima, H. Ohishi, R. Shimazaki, Y. Tominaga, Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. J. Bone Min. Metab. 35, 616–622 (2017)CrossRef
9.
A.R. Bradwell, T.C. Harvey, Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 353, 370–373 (2019)CrossRef
10.
D. Betea, A.R. Bradwell, T.C. Harvey, G.P. Mead, H. Schmidt-Gayk, B. Ghaye, A.F. Daly, A. Beckers, Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J. Clin. Endocrinol. Metab. 89, 3413–3420 (2014)CrossRef
11.
I. Horie, T. Ando, N. Inokuchi, Y. Mihara, S. Miura, M. Imaizumi, T. Usa, N. Kinoshita, I. Sekine, S. Kamihara, K. Eguchi, First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma. Endocr. J. 57, 287–292 (2010)CrossRef
12.
V.M. Howell, C.J. Haven, K. Kahnoski, S.K. Khoo, D. Petillo, J. Chen, G.J. Fleuren, B.G. Robinson, L.W. Delbridge, J. Philips, A.E. Nelson, U. Krause, K. Hammje, H. Dralle, C. Hoang-Vu, O. Gimm, D.J. Marsh, H. Morreau, B.T. The, HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J. Med Genet. 40, 657–663 (2003)CrossRef
13.
M.S. Sarquis, L.G. Silveira, F.J. Pimenta, E.P. Dias, B.T. Teh, E. Friedman, R.S. Gomez, G.C. Tavares, C. Eng, L. De Marco, Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 43, 630–640 (2008)CrossRef
14.
L. Rozhinskaya, E. Pigarova, E. Sabanova, E. Mamedova, I. Voronkova, J. Krupinova, L. Dzeranova, A. Tiulpakov, V. Gorbunova, N. Orel, A. Zalian, G. Melnichenko, I. Dedov, Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. Endocrinol. Diabetes Metab. Case Rep. 6, 0113 (2017)
15.
C.N. Clarke, P. Katsonis, T.K. Hsu, A.M. Koire, A. Silva-Figueroa, I. Christakis, M.D. Williams, M. Kutahyalioglu, L. Kwatampora, Y. Xi, J.E. Lee, E.S. Koptez, N.L. Busaidy, N.D. Perrier, O. Lichtarge, Comprehensive genomic characterization of parathyroid cancer identifies novel candidate driver mutations and core pathways. J. Endocr. Soc. 3, 544–559 (2018)CrossRef
16.
P. Piranavan, Y. Li, E. Brown, E.H. Kemp, N. Trivedi, Immune checkpoint inhibitor-induced hypoparathyroidism associated with Calcium-Sensing Receptor-Activating autoantibodies. J. Clin. Endocrinol. Metab. 104, 550–556 (2019)CrossRef
Metadata
Title
Long-term remission of disseminated parathyroid cancer following immunotherapy
Authors
Marta Sarquis
Stephen J. Marx
Albert Beckers
Arthur R. Bradwell
William F. Simonds
Maria Aparecida C. Bicalho
Adrian F. Daly
Daniela Betea
Eitan Friedman
Luiz De Marco
Publication date
01-01-2020
Publisher
Springer US
Published in
Endocrine / Issue 1/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-02136-z

Other articles of this Issue 1/2020

Endocrine 1/2020 Go to the issue

Meta-Analysis

Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis

Endocrine Genetics/Epigenetics

Detection of a novel severe mutation affecting the CYP21A2 gene in a Chilean male with salt wasting congenital adrenal hyperplasia

Letter to the Editor

Thermal ablation procedures: the need of careful appraisal

Original Article

Early postoperative HPA-axis testing after pituitary tumor surgery: reliability and safety of basal cortisol and CRH test

Endocrine imaging

Lymphangioma-like neck mass from metastatic follicular thyroid cancer

Endocrine Genetics/Epigenetics

BET bromodomain inhibition suppresses adipogenesis in mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits